Author: admin

Introduction

Tourette syndrome (TS) is a complex neurodevelopmental disorder characterized by multiple motor and vocal tics that typically begin in childhood.¹ Tics are defined as sudden, rapid, recurrent, nonrhythmic motor movements or vocalizations, which may be simple or complex in nature,^1–3 with a prevalence estimated at 0.3–0.9% among school-aged children and is notably higher in males than females.^4–6 TS often co-occurs with psychiatric comorbidities, particularly attention-deficit /hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), complicating diagnosis and management.⁷

First-line pharmacological treatments for TS include typical and atypical antipsychotics such as haloperidol, pimozide, and risperidone.⁸ While these agents can alleviate tic severity, their use is limited by variable efficacy and significant adverse effects, including sedation, weight gain, extrapyramidal symptoms, and emotional blunting.⁹ Moreover, tics often recur following drug discontinuation, underscoring the need for long-term management strategies.¹⁰ These therapeutic limitations highlight the necessity of exploring adjunctive or alternative interventions.

Traditional Chinese Medicine (TCM) has gained increasing attention as a complementary therapeutic modality in TS management.¹¹ Its appeal lies in its individualized syndrome differentiation approach, holistic focus, and relatively favorable side-effect profile. While TS does not appear in classical Chinese medical texts as a discrete disease category, its core manifestations were historically understood within the nosological frameworks of “chronic convulsion”, “wind stirring”, and “muscle spasms”.¹² These conditions were generally attributed to internal wind, phlegm, fire, qi stagnation, or organ deficiencies involving the liver, spleen, and kidney. For instance, the concept of “internal stirring of liver wind” is frequently invoked in TCM to explain convulsive movements and twitching.¹³ Moreover, recent advances in genetics and neurobiology have begun to offer a mechanistic bridge between TCM theory and modern biomedical understanding. TS has a strong genetic component, with heritability estimates of approximately 50%.¹⁴ Studies have identified associations between certain genetic polymorphisms, such as IL1RN and SLC1A3, and TS susceptibility.¹⁵ The IL1RN polymorphism has been linked to increased inflammatory responses, which may correspond to the TCM concept of “external contraction of wind-heat” or “internal wind generated by heat toxins”.¹⁶ Similarly, the SLC1A3 variant, which affects glutamate transport, may relate to the concept of hyperactive liver yang or excitatory overactivity.¹⁷ These findings suggest a potential biological basis for specific TCM syndromes and offer avenues for integrating biomedical diagnostics into TCM syndrome differentiation.

TS pathophysiology is characterized by functional abnormalities in the cortico-striato-thalamo-cortical (CSTC) circuit, dopaminergic hyperactivity, and impaired inhibitory control.¹⁸ Emerging evidence has shown that several TCM herbal compounds and formulas may target these pathophysiological mechanisms. For instance, Tianma Gouteng Decoction has been shown to reduce hyperactive liver yang and modulate dopaminergic activity,¹⁹ while Ningdong Granule can attenuate neuroinflammation by inhibiting microglial activation,²⁰ which supports the notion that TCM may exert therapeutic effects via modulation of neural and immune pathways relevant to tic generation.

This review aims to examine the therapeutic potential of TCM in conjunction with conventional treatments for TS, through the lens of genetics, pathophysiology, and clinical integration. Specifically, we will (1) describe the TCM understanding of TS based on syndrome differentiation, (2) explore the mechanisms of TCM formulas in modulating neurotransmitters, inflammatory signaling, and gene expression, (3) summarize clinical trial evidence for TCM monotherapy or integrative therapy, and (4) discuss future directions for combining individualized TCM approaches with molecular and neurological insights. By integrating modern scientific discoveries with traditional TCM principles, we aim to establish a comprehensive and biologically informed framework for TS management.

Signs and Symptoms

Tics are characterized as “sudden, rapid, brief, repetitive motor tics or speech tics”.³ Consequently, motor and speech tics are the primary symptoms of TS, exhibiting considerable variability among individuals in terms of type, severity, frequency, and complexity. Tics are generally categorized into simple and complex forms that encompass a wide range of movements and vocalizations. Simple motor tics consist of brief, repetitive movements involving a single muscle group or body part, whereas complex motor tics entail coordinated movements involving multiple muscle groups. Simple speech tics are characterized by non-word vocalizations, whereas complex speech tics may include phrases or combinations of sounds. Approximately 28.1% of individuals with TS exhibit obscene or socially inappropriate gestures or vocalizations, referred to as fecal phenomena.²¹ Research indicates that tic severity tends to be exacerbated under conditions of stress, fatigue, or excitement, while improvement is often observed during periods of mental or physical engagement or concentration.^22,23 Tics can manifest as involuntary or semi-voluntary actions, with the latter being a voluntary response to an impulsive or sensory stimulus; distinguishing between these two forms can be challenging even for seasoned clinicians.²⁴ Premonitory urges typically precede tics, although an observational study involving 21 adults with TS revealed that only 57–66% of individual tics consistently correlate with premonitory urges, depending on the measurement method.²¹

The onset of TS typically occurs between the ages of 4 and 8 years, with a peak in tic severity observed between the ages of 10 and 12 years, followed by a decline in the severity.²⁵ Many individuals experience complete remission, although tic recurrence may occur in adulthood.²⁶ Numerous studies have demonstrated that the severity of tics and associated psychiatric comorbidities during childhood significantly increase the risk of tic persistence into adulthood.²⁷ Consequently, a substantial number of children and adults may experience severe tics that necessitate emergency interventions. The term “phonetic tic” is preferred over “vocal tic”, as involuntary sounds may originate from various anatomical structures, including the mouth, nose, larynx, and pharynx, rather than solely from vocal cords. In certain cases, speech tics may be pronounced enough to cause hoarseness or even vocal cord damage.²⁸ In addition to producing simple nonsensical sounds, individuals with TS frequently articulate meaningful phrases or utterances, including swearing and obscenity, a phenomenon known as coprolalia.

For some patients with TS, tics can not only be bothersome, but also debilitating. For instance, blepharospasm, characterized by increased blinking, may intermittently obstruct vision, potentially rendering the individual functionally blind, which can interfere with activities such as driving.²⁹ A survey of 228 individuals with TS or chronic tic disorders revealed that 9% reported difficulties in passing a driving test.³⁰ Participants lacking a driver’s license reported more severe tics than those who possessed one, with 60.7% of the former attributing their inability to obtain a license for the presence of tics.³⁰

Coprophenomena are common manifestations of TS, encompassing socially inappropriate verbal expressions (coprolalia) or gestures (copropraxia) that contain offensive content such as vulgarity, obscenity, religious profanity, or racial slurs. These expressions are typically not motivated by direct anger or frustration, nor are they merely emphasis.³¹ The presence of fecal phenomena may contribute to social stigma often experienced by individuals with TS. As the peak severity of TS coincides with the emergence of fecal phenomena, patients may become increasingly withdrawn and face social rejection.³² More critically, behaviors such as shouting obscenities or engaging in inappropriate conduct in public or religious settings can lead to bullying and other aggressive or criminal behaviors.^33,34

Self-injurious behavior (SIB) is defined as repeated, intentional, and persistent self-harm that is not indicative of a suicide attempt (ie, non-suicidal self-harm).³⁵ Although SIB and suicidal behavior may overlap, they differ in terms of frequency, intent, and lethality.³⁶ A review of 20 cohort studies estimated the prevalence of SIB in TS to be approximately 35%, with significant variability across studies ranging from 14% to 66%.^35,37 SIB in TS may arise directly from tics or pathological compulsions that lead to “self-directed” harm, such as self-cutting, self-punching, self-biting, or self-poisoning, through the ingestion of harmful substances.³⁸ Additionally, “extroverted” forms of SIB may involve striking walls, floors, or furniture with various body parts, characterized by an intent to inflict self-harm rather than damage inanimate objects.^38,39 This form of SIB should be differentiated from attacks on physical objects, although they may coexist. SIB in TS is often associated with various skin lesions, including ecchymosis, cuts, and scratches.⁴⁰

TS frequently co-occurs with other mental and behavioral disorders, including obsessive-compulsive behavior or obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), autism spectrum disorders, anxiety, depression, sleep disorders, and self-harm behaviors.⁴¹ A cross-sectional study involving 1374 individuals indicated that isolated TS is relatively uncommon; up to 88% of TS patients are diagnosed with at least one additional psychiatric disorder during their lifetime and 58% are diagnosed with two or more comorbidities.⁴² The most prevalent comorbidities include ADHD and OCD, with an estimated 72% of patients diagnosed with one of these conditions.⁴² Although the onset of these comorbidities varies among individuals, ADHD is often the earliest to manifest, followed by OCD and mood disorders.²⁹ Furthermore, consistent with findings related to other psychiatric disorders, individuals with TS and comorbidities exhibit an increased risk of mortality from both natural and unnatural causes compared to those with TS alone, although the underlying factors contributing to this increased risk remain unclear.⁴³

Diagnosis

TS is diagnosed through clinical evaluation that includes a comprehensive assessment of an individual’s medical history. According to the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a diagnosis of TS requires that the onset of tics occur prior to the age of 18. Furthermore, the individual must exhibit at least two motor tics and one vocal tic, although the presence of tics for a minimum duration of one year is not a prerequisite. The DSM-5 categorizes tic disorders into transient tic disorders, persistent tic disorders, and TS, although there is a proposal to conceptualize these conditions as part of a spectrum.^44,45 Although a familial history of tics and TS can be informative, it is not essential for diagnosis.

Various rating scales are available to evaluate the symptoms of individuals with TS across all age groups,⁴⁶ with the Yale Global Tic Severity Scale (YGTSS) being the most widely utilized instrument. Due to the inherent variability and fluctuation of symptoms, guidelines⁸ advocate for a multifaceted approach to measuring symptom severity, which includes direct observation in clinical settings, historical accounts from the individual and their family, and video-based assessments.

The diagnosis and assessment of TS can be particularly complex due to the clinical heterogeneity of the disorder, suppressibility of tics, and temporal variability of symptoms. Consequently, diagnosis may be delayed by a period ranging from 3 to 11 years following the initial onset of symptoms, with approximately 73% of patients experiencing an initial misdiagnosis. This misdiagnosis is often attributed to a general lack of awareness regarding TS among both the public and healthcare professionals.^47,48 Currently, no early diagnostic markers, such as imaging, blood tests, or cerebrospinal fluid (CSF) biomarkers, have been identified to facilitate diagnosis before the manifestation of symptoms. However, some studies indicate that certain individuals may be predisposed to developing tics, particularly those exhibiting behavioral issues, symptoms of autism spectrum disorder, obsessive-compulsive behaviors, and emotional difficulties, as suggested by a study conducted by a multicenter consortium.⁴⁶ Enhancing the awareness of TS and its associated risk factors may empower caregivers and healthcare providers to identify tics and initiate treatment at an earlier stage.

The accurate diagnosis of TS is often complicated^49,50 by the presence of comorbid behavioral disorders and the challenge of differentiating between tics and functional tic-like behaviors.⁵¹ Functional tic-like behaviors are characterized by a sudden and late onset of symptoms, asymptomatic fluctuations, a higher prevalence in females compared than in males, and more complex movements. Early and precise diagnosis, along with timely intervention, is crucial as TS symptoms can significantly hinder social integration and cognitive development. Effective treatment can alleviate the symptoms and mitigate the challenges faced by individuals with TS and their caregivers.

Genetics

Genetic investigations of TS have evolved in several phases. Initial research focused on multigenerational family lineages, which indicated a potential Mendelian inheritance pattern. However, subsequent segregation analyses have revealed a more intricate inheritance model.⁵² Advances in technology have facilitated family, twin, and molecular genetic studies that have provided substantial evidence for the genetic underpinnings of TS, estimating heritability to be between 50% and 80%.⁵³ Recently, large-scale collaborative initiatives, such as the Tourette International Collaborative Genetics (TIC Genetics) study, have emerged to identify genetic risk factors for TS, encompassing both common and rare variants as well as potentially complex polygenic or monogenic inheritance patterns.⁵⁴ These studies used extensive patient cohorts and open-access databases. Furthermore, the application of Genome-Wide Association Studies (GWAS), whole exome sequencing (WES), and whole genome sequencing (WGS) has opened new avenues for identifying genes and pathways associated with TS.⁵⁵

Family, twin, and molecular genetic studies provide robust support for the existence of a genetic component in TS that is characterized by high heritability.⁵³ The genetic architecture of TS is complex, involving both common and rare variants. Common variants may influence morbidity risk through the cumulative effect of minor contributions, whereas rare variants may exert more significant impacts.⁵² Numerous candidate genes and chromosomal regions linked to TS risk have been identified, implicating biological pathways related to neurodevelopment, neurotransmission, and synaptic function.⁵³ For instance, certain genes may influence the metabolism and transmission of neurotransmitters such as dopamine and glutamate, which are associated with the manifestation of TS. Additionally, evidence suggests a genetic connection between TS and autism spectrum disorders, potentially mediated by neurodevelopmental pathways involving a series of transsynaptic complex-related genes.⁵⁶

The etiology of TS is multifactorial, involving interactions among genetic, environmental, and immune factors. Genetic predisposition has been shown to exacerbate tic severity, comorbidities, and psychosocial and educational challenges in children with TS.⁵⁷ For example, individuals carrying the IL1RN (1) allele exhibit a 7.65-fold increased risk of developing TS compared with those carrying the IL1RN (2) allele, indicating that the IL1RN gene may serve as a valuable marker for susceptibility to TS.⁵⁸ Concurrently, environmental factors such as prenatal exposure to tobacco have also been linked to the onset and severity of TS.⁵⁹ Gene-environment interaction studies have identified specific gene loci that interact with prenatal and perinatal stressors to influence tic severity, although these findings require further validation.⁶⁰

TS exhibits significant genetic heterogeneity, posing a challenge for genetic research. Variability in the genes and chromosomal regions associated with TS across different studies suggests the involvement of multiple genetic mechanisms in its etiology. For instance, distinct disease-causing genes or gene combinations may be present in different families or populations.⁵² Structural variation studies have revealed that TS-related structural variations in various families involve different genes, such as deletions or insertions in LDLRAD4, B2m, USH2A, and ZNF765, which affect diverse biological processes, including synaptic vesicle endocytosis, cell-front organization, and neurite growth signaling.⁶¹ This genetic heterogeneity may contribute to a range of clinical phenotypes, complicating the identification of uniform inheritance patterns in genetic studies of TS.

The debate persists regarding whether TS is attributable to multiple genes or a single gene. Early investigations suggested that the inheritance pattern of TS in certain families resembled Mendelian inheritance, leading to the proposal of a single-gene inheritance model.⁵² However, as research has progressed, accumulating evidence has indicated that TS may be a polygenic disorder, with the cumulative or interactive effects of multiple genes contributing to its manifestation. For instance, GWAS findings have identified multiple loci associated with TS risk, albeit with minimal effects attributed to individual loci, thereby supporting the notion of polygenic inheritance.⁶² Additionally, some rare single-gene mutations, such as those in HDC, have been linked to TS phenotypes, although such instances are relatively uncommon. Consequently, it is posited that TS may arise from both polygenic and monogenic inheritance, with the precise mechanisms warranting further investigation.

Research on the genetics of TS has raised numerous ethical considerations. It is imperative to ensure informed consent from patients and participants, particularly children, necessitating the consent of their guardians and, where feasible, the patients themselves. For instance, during genetic testing and related research, participants should receive comprehensive explanations regarding the objectives, methodologies, potential risks, and benefits of the study. Moreover, the dissemination and application of research findings should be approached with caution to mitigate unnecessary psychological burdens or discrimination against patients. In terms of treatment, particularly with emerging interventions such as deep brain stimulation (DBS) in pediatric populations, it is essential to carefully weigh the risks and benefits to ensure that the treatment aligns with the best interests of the patients along with the establishment of appropriate ethical guidelines and protocols.

Pathophysiology

Robust evidence derived from genetic studies and neuroimaging techniques provides substantial support for the classification of TS as a neurodevelopmental disorder.⁶³ Comparative neuroimaging research involving adults and children diagnosed with TS has identified notable differences in functional brain connectivity. Additionally, the developmental trajectories observed in individuals with TS suggest distinct patterns; specifically, functional brain connections in children with TS appear more advanced, while those in adults with TS seem less mature when compared to age-matched control groups.⁶⁴ These discrepancies may be attributable to variations in cellular and axonal pruning processes, which can be influenced by both genetic and environmental factors.⁶⁵ In summary, it is likely that a combination of genetic and environmental influences contributes to widespread dysfunction within neuronal networks, potentially leading to the manifestation of symptoms associated with TS.^65,66

The primary focus of TS research is to elucidate the mechanisms underlying the tic generation. The observation that tics exhibit similarities to voluntary behaviors—being subject to inhibition upon request yet manifesting excessively and without an apparent purpose—carries significant pathophysiological implications. Specifically, this suggests that the neural pathways responsible for voluntary behavior are also implicated in tic production. This indicates that certain fundamental neural structures associated with motor inhibitory control may be incapable of suppressing the emergence of aberrant motor programs. In contrast, other neural structures that provide top-down inhibitory regulation of the execution of these unexpressed motor programs appear to operate within normal parameters.⁶⁷

Research has revealed both structural and functional abnormalities at various levels within the corticostriatothalamocortical (CSTC) loops of individuals with TS. These circuits are essential for the development and execution of voluntary behaviors, indicating a potential correlation between the observed alterations in these structures and the initiation of tics.⁶⁷ Furthermore, two neuropathological studies conducted on a limited cohort of adults with TS who had previously undergone pharmacological treatment provided evidence of structural changes in the composition of inhibitory interneuronal populations, specifically GABAergic and cholinergic neurons. These alterations were particularly noted in the sensorimotor region of the striatum⁶⁸ and globus pallidus intersegment.⁶⁶ These findings support the hypothesis of a functional imbalance between inhibitory and excitatory processes within these neural structures.

At the network level, tics may arise from inhibitory dysfunction within the sensorimotor cortex-basal ganglia network,⁵⁷ which includes alterations in striatal inhibitory microcirculation^68,69 and difficulties with autoinhibitory mechanisms.⁷⁰ This impairment in the ability to delay action is associated with the severity of tics.⁷¹ Conversely, volitional inhibition, assessed through either active or reactive inhibition, remains relatively stable in individuals with TS⁶⁸ and is linked to their capacity to suppress tics.⁷²

While informative, the disinhibition model fails to account for several fundamental characteristics of tic disorders, including fluctuations in personality and the presence of premonitory impulses. An alternative hypothesis posits that tics may be indicative of exaggerated and sustained behavioral patterns reinforced by an abnormal increase in dopamine release.⁷³ Evidence supporting this notion suggests that dopamine-related reward-guided learning, commonly referred to as reinforcement learning, is heightened in individuals with TS.⁷⁴ Furthermore, individuals with TS often rely on habitual behaviors when not under the influence of medication.⁷⁵ Consequently, the hypothesis that the increased aberrant tetanic release of dopamine facilitates the execution of learned behaviors through direct or indirect plastic changes within the cortico-basal ganglia pathway has garnered attention.⁷³ This perspective posits that tics, as habitual and learned behaviors, may elucidate the phenomenon of premonitory impulses. Specifically, the execution of tics may serve to terminate these impulses, thereby eliciting positive prediction errors and phasic dopamine release that further reinforce the learning of tics.⁷⁶ The prevailing model of premonitory impulses suggests that aberrant processing of interoceptive and exteroceptive stimuli may give rise to these impulses, which subsequently initiate behavioral responses and lead to the execution of tics via the cortico-basal ganglia sensorimotor network.⁷⁷

The morbidity mechanism of TS is summarized as follows, as shown in Figure 1.

Figure 1 Pathophysiological Mechanisms Underlying Tourette Syndrome.

TCM’s Perception of TS

While TS does not have a direct equivalent in the classical texts of TCM, its clinical manifestations can be categorized under the concepts of “chronic convulsion” and “muscle disorders”. TCM posits that the etiology and pathogenesis of TS are multifaceted, with significant associations with liver, spleen, and kidney.¹² The liver is responsible for the smooth circulation of qi and its regulation; when emotional disturbances occur, liver function may become impaired, leading to qi stagnation that can transform into fire, resulting in what is termed “liver wind”, which may precipitate convulsions. The spleen serves as the foundation for acquired vitality and is the source of qi and blood, and deficiency in spleen function can lead to inadequate nourishment of tendons and vessels or the production of phlegm, which may disrupt mental clarity and contribute to convulsive episodes. The kidney, regarded as the source of congenital vitality, is responsible for storing essence and generating marrow. This can result in kidney essence deficiency, leading to inadequate nourishment of the brain and marrow, which may also manifest as twitching symptoms. Furthermore, children exposed to external pathogenic factors, such as wind-heat or damp-heat, may experience disturbances in the liver wind, contributing to the onset of TS. A study investigating gene polymorphisms in a cohort of 159 children with TS revealed a significantly higher frequency of the IL1RN (*) 1 allele in affected individuals than in healthy controls, indicating the potential role of immune factors in the pathogenesis of TS. This finding aligns with the TCM perspective that the interplay between internal and external factors is crucial in the development of the disorder.⁵⁸

In recent years, TCM has made notable advancements in the elucidation of the pathological mechanisms associated with TS. TCM can modulate these mechanisms via various pathways. From the neurotransmitter perspective, TCM can influence the synthesis, release, and metabolism of neurotransmitters, thereby restoring their equilibrium. For instance, research has demonstrated that certain TCM formulations can modulate the expression of dopamine receptors, thereby enhancing dopaminergic neurotransmission.⁷⁸ Furthermore, in terms of the immune response, specific TCM interventions have been shown to regulate immune function and mitigate neuroinflammation. For example, Ningdong granules have been observed to inhibit the neuroinflammatory response in a rat model of tic disorders induced by 3,3’-iminodipropionitrile (IDPN), leading to a reduction in the release of inflammatory mediators.²⁰ Additionally, TCM may exert regulatory effects on gene expression and enhance neural plasticity, contributing to the amelioration of the pathological conditions associated with TS.

Research on genetic polymorphisms has indicated that certain genetic variations in patients with TS are associated with susceptibility to the disorder. TCM may exert therapeutic effects by modulating the expression of these pertinent genes. For instance, investigations into SLC1A3 have revealed that its sequence variations may correlate with the incidence of TS, suggesting that TCM could influence glutamate transport by altering the functionality of this gene, thereby alleviating symptoms.⁷⁹ Additionally, neuroimaging studies have demonstrated that individuals with TS exhibit abnormalities in both brain structure and function, with observable alterations in brain activity following TCM interventions. Functional magnetic resonance imaging (fMRI) studies have shown that TCM treatment can modulate neuronal activity in brain regions associated with TS and enhance neural functional connectivity. These findings provide valuable insights into the underlying pathological mechanisms through which TCM may facilitate the treatment.

The Mechanism of TCM in the Treatment of TS

The therapeutic mechanisms of TCM in the management of TS are characterized by their engagement with multiple targets and pathways. From a neurotransmitter perspective, numerous studies have demonstrated that TCM can effectively address imbalances in neurotransmitters, such as dopamine, glutamate, and gamma-aminobutyric acid. Network pharmacology analyses of Qiangzhi decoction have revealed that its active components interact with various targets associated with the dopamine system, thereby influencing dopamine metabolism and signal transduction, which ultimately leads to the amelioration of tic symptoms.⁷⁸ Furthermore, from the standpoint of neuroinflammation, Ningdong granules have been shown to inhibit the activation of striatal microglia in a rat model of tics induced by 3,3’-iminodipropionitrile (IDPN). This intervention results in a reduction in inflammatory mediators, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), thereby contributing to the control of tic manifestations.²⁰ Additionally, ChangPu YuJin Tang has been found to protect neuronal cells from structural damage by modulating the brain-derived neurotrophic factor (BDNF)/tyrosine kinase receptor B (TrkB) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathways, leading to improvements in the symptoms observed in rats with TS.⁸⁰

TCM Treatment of TS Commonly Used Prescriptions and Drugs

Numerous TCM formulations are utilized in the management of TS, including Tianma Gouteng Decoction, Chaihu Shugan Powder, and Liuwei Dihuang Pill. Tianma Gouteng Decoction is recognized for its ability to calm the liver, alleviate wind, clear heat, promote blood circulation, and nourish the liver and kidneys. It is particularly effective for tic symptoms associated with hyperactivity of the liver yang and the internal movement of the liver wind. Chaihu Shugan Powder is known for its capacity to soothe the liver and regulate the flow of qi, demonstrating efficacy in addressing twitching resulting from emotional disturbances and liver qi stagnation. Liuwei Dihuang Pill primarily focuses on nourishing kidney-yin and is frequently used for TS characterized by liver-kidney yin deficiency.

In terms of individual herbal components, commonly utilized TCM herbs include Gastrodia elata, Uncaria rhynchophylla, Concha Haliotidis, Bupleurum chinense, Paeonia lactiflora, and Rehmannia glutinosa. Specifically, Rhizoma Gastrodiae is effective in stopping wind and spasms while suppressing liver yang; Ramulus Uncariae Cum Uncis serves to clear heat, calm the liver, and arrest convulsions; Concha Haliotidis aids in calming the liver and suppressing yang, as well as enhancing vision; Radix Bupleuri is known to soothe the the liver and alleviate depression; Radix Paeoniae Alba nourishes the blood and softens the liver; and Radix Rehmanniae Preparata is utilized to nourish yin and tonify the kidneys.

Recent network pharmacology studies have indicated that certain components found in Xiaoyao Powder and Chaihu Shugan Powder, such as Bupleurum and Paeonia lactiflora, herbs commonly employed in the treatment of premenstrual syndrome, may exert their therapeutic effects through the regulation of multiple targets and signaling pathways. This finding offers valuable insights into the treatment of TS.⁸¹

The TCM syndrome differentiation and treatment pathway of TS are summarized as follows, as shown in Figure 2.

Figure 2 Traditional Chinese Medicine Syndrome Differentiation and Corresponding Treatment Strategies for Tourette Syndrome.

Clinical Practice of TCM Combined Therapy for TS

Fan et al⁸² conducted a randomized controlled trial (RCT) to evaluate the efficacy of Jianpi Shugan Huatan decoction in children diagnosed with TS and its impact on neurotransmitter secretion. The study involved 98 children with TS, who were randomly assigned to either a control group or an observation group, with 49 participants in each group. The control group received tiapride hydrochloride, while the observation group was administered Jianpi Shugan Huatan Decoction. After an 8-week treatment period, the researchers compared the clinical efficacy, disease severity, neurotransmitter secretion levels, recurrence rates, and adverse reactions between the two groups. The findings indicated that the combination of Jianpi Shugan Huatan decoction and tiapride hydrochloride tablets significantly reduced TS severity, enhanced neurotransmitter secretion levels, improved therapeutic outcomes, and demonstrated a favorable safety profile with a low likelihood of relapse.

Liu Shan et al⁸³ also designed an RCT to assess the clinical efficacy of Changma Xifeng Tablets in conjunction with Haloperidol Tablets in treating children with TS. This study included 96 children with TS who were divided into a control group and a treatment group, each comprising 48 participants. The control group received haloperidol tablets, while the treatment group was administered Changma Xifeng Tablets alongside haloperidol. The treatment duration was four weeks, during which clinical efficacy, cognitive development, therapeutic effects, electroencephalogram (EEG) results, YGTSS scores, and serum neurotransmitter levels were evaluated and compared. The results suggested that the combination of Changma Xifeng and haloperidol tablets effectively improved clinical symptoms, cognitive development, EEG results, and serum neurotransmitter levels (dopamine, norepinephrine, and serotonin) in children with TS.

Qiu et al⁸⁴ conducted an RCT to investigate the clinical efficacy of Xifeng granules combined with psychological interventions in treating children with TS. The study included 120 children with TS who were randomly assigned to a study group (n = 60) and a control group (n = 60). The control group received treatment with dopamine receptor blocker tiapride tablets, while the study group was treated with Xifeng granules in conjunction with psychological intervention. The researchers compared the clinical efficacy, TCM syndrome scores, YGTSS scores, recurrence rates, and adverse reactions between the two groups. The results indicated that the combination of Xifeng granules and psychological intervention yielded significant clinical improvements in children with TS, effectively alleviating symptoms and demonstrating a high safety profile.

Zhang Yao et al⁸⁵ designed an RCT to evaluate the clinical efficacy of acupuncture combined with Anshen Zhicheng Granule in treating pediatric TS characterized by hyperactivity of heart-liver fire. The study included 118 pediatric patients with TS who were randomly assigned to two groups: Group A (n = 59) received acupuncture combined with Anshen Zhicheng granules, whereas Group B (n = 59) was treated with Tiapride Hydrochloride Tablets. The researchers compared the clinical efficacy, YGTSS scores, American Spinal Injury Association scores, and changes in peripheral blood neurotransmitter levels before and after treatment. Adverse reactions were also assessed. The findings revealed that acupuncture combined with Anshen Zhicheng Granule effectively alleviated motor and vocal tics in children with TS of the hyperactivity of heart-fire and liver-fire types, improved neurotransmitter levels and neurological function, and exhibited superior efficacy and a lower incidence of adverse reactions compared to Tiapride Hydrochloride Tablets.

Beiru et al⁸⁶ conducted an RCT to assess the clinical efficacy of auricular point sticking combined with Yizhining Shenye in treating TS. The study included 90 children with TS who were randomly divided into two groups: the control group (n = 37) received Yizhiningshen liquid, while the treatment group (n = 53) received auricular point sticking in combination with Yizhiningshen liquid. The researchers evaluated the YGTSS and side effects scale before treatment, 12 weeks post-treatment, and 12 weeks after treatment. The results indicated that auricular point sticking combined with yizhiningshenye was both safe and effective in treating TS, with no significant toxic or side effects, and demonstrated superior outcomes compared to monotherapy with medication.

The mechanism of action of comprehensive TCM treatment of TS is summarized in Figure 3.

Figure 3 Integrated Treatment Framework Combining Traditional Chinese and Western Medicine for Tourette Syndrome.

Challenges on the Specificity of TCM in TS

Despite growing interest in the integration of TCM for the management of TS), concerns persist in mainstream biomedical discourse regarding the specificity, reproducibility, and scientific validation of TCM interventions, which largely center on methodological limitations, such as small sample sizes, inadequate placebo controls, lack of blinding, and difficulties in isolating pharmacologically active constituents within multi-herbal formulations.

First, many clinical trials evaluating TCM interventions for TS are single-center studies with limited sample sizes, which may restrict generalizability and inflate effect sizes due to random variation or selection bias. A 2020 meta-analysis of randomized controlled trials (RCTs) on TCM for TS highlighted generally favorable outcomes but also underscored that most included studies exhibited a high or unclear risk of bias due to suboptimal randomization procedures and limited blinding.⁸⁷ Placebo effects in neuropsychiatric conditions, particularly those with fluctuating symptoms such as TS, are well-documented and may account for part of the observed benefit in some trials that lack rigorous controls.

Second, the complexity of TCM formulas presents substantial challenges for mechanistic interpretation.⁸⁸ Unlike single-molecule Western drugs, TCM prescriptions often contain multiple herbal ingredients with synergistic or antagonistic interactions, which complicates the standardization of dose, bioavailability, and pharmacokinetics.⁸⁸ Efforts to deconstruct multi-component TCM formulas using systems biology and network pharmacology are still in their early stages and require further refinement to reliably identify active constituents and their molecular targets.⁸⁹

Furthermore, from the standpoint of evidence-based medicine, the current body of literature evaluating TCM’s efficacy for TS is disproportionately weighted toward Chinese-language publications, with underrepresentation in high-impact international journals.⁹⁰ This publication pattern may reflect regional preferences or positive publication bias. Therefore, calls for more rigorous, multicenter, placebo-controlled, double-blind RCTs have been echoed by international experts to validate preliminary findings and ensure reproducibility across diverse populations.

It is also important to acknowledge the ongoing epistemological debate regarding syndrome differentiation in TCM, which does not conform to nosological systems used in modern biomedicine.⁹¹ While TCM syndrome classification offers a personalized treatment rationale, it may introduce subjectivity that limits replicability. As such, establishing robust diagnostic consensus criteria and integrating biomarker-informed stratification may help bridge this methodological gap.

Overall, while TCM offers a promising complementary approach for TS, the aforementioned concerns underscore the need for continued methodological rigor, pharmacological dissection of active components, and cross-disciplinary collaboration to validate and refine TCM-based interventions.

Summary

The application of TCM in the treatment of TS has shown promising potential; however, it continues to encounter substantial scientific and clinical scrutiny due to the lack of standardized formulations, limited reproducibility of results due to herbal variability, and the scarcity of large-scale, multicenter randomized controlled trials. While TCM interventions are generally associated with fewer adverse effects compared to conventional pharmacotherapy, the long-term safety and potential toxicity of certain herbal components require further investigation. Moreover, the multi-component, multi-target nature of TCM complicates mechanistic elucidation within the reductionist framework of modern biomedicine.

This review highlights that bridging the gap between traditional TCM concepts and contemporary neurobiological understanding can be facilitated by integrating genetic and pathophysiological insights. For instance, polymorphisms in genes have shown preliminary alignment with TCM syndromes such as “wind-heat invasion” and “liver yang hyperactivity”. Furthermore, abnormalities in the CSTC circuit, dopaminergic hyperactivity, and microglial activation, which are core pathophysiological features of TS, may conceptually correspond to TCM patterns such as “internal wind” or “phlegm-heat”. Several TCM formulations have demonstrated modulatory effects on these biological processes, including the downregulation of IL1RN expression and the restoration of dopaminergic balance, suggesting a plausible basis for their therapeutic action through gene regulation and pathway modulation.

To enhance the clinical validity of TCM for TS, future studies could prioritize mechanistic investigations using tools such as molecular genetics, transcriptomics, and systems neuroscience, as they may provide critical insight into how individual herbs or multi-herbal formulas regulate neurotransmitter systems and gene expression networks implicated in TS. High-quality evidence could also require rigorously designed randomized controlled trials with multicenter collaboration, standardized herbal processing protocols, and harmonized diagnostic criteria. Notably, standardizing herbal cultivation and processing would reduce batch-to-batch variability, a necessary step toward TCM’s recognition in international clinical guidelines. Artificial intelligence and bioinformatics may further facilitate biomarker identification and pattern classification, contributing to precision-guided syndrome differentiation and personalized therapy.

From a clinical perspective, integrated TCM-Western medicine regimens have demonstrated superior outcomes compared to monotherapies. Meta-analyses and recent randomized controlled trials have shown that combining TCM with pharmacological treatments reduces tic severity and the incidence of adverse drug reactions, supporting their consideration as adjunctive first-line options, particularly in pediatric patients with poor tolerability to antipsychotics. Moreover, non-pharmacological TCM modalities, such as acupuncture and massage, may provide additional symptom relief and functional improvement when incorporated into broader rehabilitation strategies. In summary, aligning TCM theory with genetic and pathophysiological frameworks not only enhances its scientific interpretability but also offers a pathway for its integration into modern clinical practice. Future progress would depend on interdisciplinary collaboration, methodological rigor, and regulatory standardization to transform preliminary findings into biologically plausible, clinically meaningful, and globally acceptable interventions for TS.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Cavanna AE, Purpura G, Riva A, et al. Comorbid tics and stereotypies: a systematic literature review. Neurol Sci. 2024;45(2):477–483.

2. Baizabal-Carvallo JF, Jankovic J. The clinical characterization of blocking tics in patients with tourette syndrome. J Mov Disord. 2023;16(2):163–167.

3. Johnson KA, Worbe Y, Foote KD, et al. Tourette syndrome: clinical features, pathophysiology, and treatment. Lancet Neurol. 2023;22(2):147–158.

4. Scharf JM, Miller LL, Gauvin CA, et al. Population prevalence of Tourette syndrome: a systematic review and meta‐analysis. Mov Disord. 2015;30(2):221–228. doi:10.1002/mds.26089

5. Levine JL, Szejko N, Bloch MH. Meta-analysis: adulthood prevalence of Tourette syndrome. Prog Neuro Psychopharmacol Biol Psychiatry. 2019;95:109675. doi:10.1016/j.pnpbp.2019.109675

6. Garcia-Delgar B, Servera M, Coffey BJ, et al. Tic disorders in children and adolescents: does the clinical presentation differ in males and females? A report by the EMTICS group. Eur Child Adolesc Psychiatry. 2022;31(10):1539–1548.

7. Baizabal-Carvallo JF, Cavanna AE, Jankovic J. Tics emergencies and malignant Tourette syndrome: assessment and management. Neurosci Biobehav Rev. 2024;159:105609.

8. Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022;31(3):425–441. doi:10.1007/s00787-021-01899-z

9. Billnitzer A, Jankovic J. Current management of tics and Tourette syndrome: behavioral, pharmacologic, and surgical treatments. Neurotherapeutics. 2020;17(4):1681–1693. doi:10.1007/s13311-020-00914-6

10. Martino D. Update on the treatment of tics in Tourette syndrome and other chronic tic disorders. Curr Treat Options Neurol. 2020;22(4):10. doi:10.1007/s11940-020-0620-z

11. Wang N, Qin DD, Xie YH, et al. Traditional Chinese medicine strategy for patients with Tourette syndrome based on clinical efficacy and safety: a meta-analysis of 47 randomized controlled trials. Biomed Res Int. 2021;2021(1):6630598. doi:10.1155/2021/6630598

12. Lee MH. A single case of Tourette’s syndrome treated with traditional Chinese medicine. J Acupunct Meridian Stud. 2017;10(1):55–61. doi:10.1016/j.jams.2016.12.005

13. Chan HP. Acupuncture for Stroke Rehabilitation: Three Decades of Information From China. Blue Poppy Enterprises, Inc.; 2006.

14. Abdallah SB, Fernandez TV. Genetic susceptibility in Tourette syndrome [M]. In: Tourette Syndrome. Oxford University Press;2022:125.

15. Paschou P, Fernandez TV, Sharp F, et al. Genetic susceptibility and neurotransmitters in Tourette syndrome. Int Rev Neurobiol. 2013;112:155–177.

16. Reiner AP, Wurfel MM, Lange LA, et al. Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation. Arterioscler Thromb Vasc Biol. 2008;28(7):1407–1412. doi:10.1161/ATVBAHA.108.167437

17. Chan K, Busque SM, Sailer M, et al. Loss of function mutation of the Slc38a3 glutamine transporter reveals its critical role for amino acid metabolism in the liver, brain, and kidney. Pflugers Arch. 2016;468(2):213–227. doi:10.1007/s00424-015-1742-0

18. Liberati AS, Perrotta G. Neuroanatomical and functional correlates in tic disorders and Tourette’s syndrome: a narrative review. ibrain. 2024;10(4):439–449. doi:10.1002/ibra.12177

19. Dong H, Zhang S, Du W, et al. Pharmacodynamics and metabonomics study of Tianma Gouteng Decoction for treatment of spontaneously hypertensive rats with liver-yang hyperactivity syndrome. J Ethnopharmacol. 2020;253:112661. doi:10.1016/j.jep.2020.112661

20. Zhao L, Cheng N, B Sun, et al. Regulatory effects of Ningdong granule on microglia-mediated neuroinflammation in a rat model of Tourette’s syndrome. Biosci Trends. 2020;14(4):271–278. doi:10.5582/bst.2020.03262

21. Sambrani T, Jakubovski E, Müller-Vahl KR. New insights into clinical characteristics of Gilles de la Tourette syndrome: findings in 1032 patients from a single German center. Front Neurosci. 2016;10:415. doi:10.3389/fnins.2016.00415

22. Barnea M, Benaroya-Milshtein N, Gilboa-Sechtman E, et al. Subjective versus objective measures of tic severity in Tourette syndrome – The influence of environment. Psychiatry Res. 2016;242:204–209. doi:10.1016/j.psychres.2016.05.047

23. Robinson S, Hedderly T. Novel psychological formulation and treatment of “Tic Attacks” in Tourette Syndrome. Front Pediatr. 2016;4:46. doi:10.3389/fped.2016.00046

24. Jankovic J. Tourette syndrome. Phenomenology and classification of tics. Neurol Clin. 1997;15(2):267–275. doi:10.1016/S0733-8619(05)70311-X

25. Groth C. Tourette syndrome in a longitudinal perspective. Clinical course of tics and comorbidities, coexisting psychopathologies, phenotypes and predictors. Dan Med J. 2018;65(4):1–24.

26. Jankovic J, Gelineau-Kattner R, Davidson A. Tourette’s syndrome in adults. Mov Disord. 2010;25(13):2171–2175. doi:10.1002/mds.23199

27. Mataix-Cols D, Isomura K, Brander G, et al. Early-life and family risk factors for tic disorder persistence into adulthood. Mov Disord. 2023;38(8):1419–1427. doi:10.1002/mds.29454

28. Munhoz RP, Scorr LM, Factor SA. Movement disorders emergencies. Curr Opin Neurol. 2015;28(4):406–412. doi:10.1097/WCO.0000000000000212

29. Makhoul K, Jankovic J. Tourette syndrome and driving. Mov Disord Clin Pract. 2021;8(5):763–768. doi:10.1002/mdc3.13225

30. fernández de La Cruz L, Ringberg H, Anderson S, et al. driving with tic disorders: an international survey of lived experiences. Mov Disord Clin Pract. 2021;8(3):412–419. doi:10.1002/mdc3.13177

31. Van Lancker D, Cummings JL. Expletives: neurolinguistic and neurobehavioral perspectives on swearing. Brain Res Brain Res Rev. 1999;31(1):83–104. doi:10.1016/S0165-0173(99)00060-0

32. Kakusa B, Saluja S, Tate WJ, et al. Robust clinical benefit of multi-target deep brain stimulation for treatment of Gilles de la Tourette syndrome and its comorbidities. Brain Stimul. 2019;12(3):816–818. doi:10.1016/j.brs.2019.02.026

33. Jankovic J, Kwak C, Frankoff R. Tourette’s syndrome and the law. J Neuropsychiatry Clin Neurosci. 2006;18(1):86–95. doi:10.1176/jnp.18.1.86

34. Virtanen S, Sidorchuk A, Fernández de la Cruz L, et al. Association of Tourette syndrome and chronic tic disorder with subsequent risk of alcohol- or drug-related disorders, criminal convictions, and death: a population-based family study. Biol Psychiatry. 2021;89(4):407–414. doi:10.1016/j.biopsych.2020.09.014

35. Fischer JF, Mainka T, Worbe Y, et al. Self-injurious behaviour in movement disorders: systematic review. J Neurol Neurosurg Psychiatry. 2020;91(7):712–719. doi:10.1136/jnnp-2019-322569

36. Hamza CA, Stewart SL, Willoughby T. Examining the link between nonsuicidal self-injury and suicidal behavior: a review of the literature and an integrated model. Clin Psychol Rev. 2012;32(6):482–495. doi:10.1016/j.cpr.2012.05.003

37. Stafford M, Cavanna AE. Prevalence and clinical correlates of self-injurious behavior in Tourette syndrome. Neurosci Biobehav Rev. 2020;113:299–307. doi:10.1016/j.neubiorev.2020.03.022

38. Baizabal-Carvallo JF, Alonso-Juarez M, Jankovic J. Self-injurious behavior in Tourette syndrome. J Neurol. 2022;269(5):2453–2459. doi:10.1007/s00415-021-10822-0

39. Robertson MM, Eapen V, Singer HS, et al. Gilles de la Tourette syndrome. Nat Rev Dis Primers. 2017;3:16097.

40. Jankovic J, Sekula S. Dermatological manifestations of Tourette syndrome and obsessive-compulsive disorder. Arch Dermatol. 1998;134(1):113–114.

41. Pringsheim T, Ganos C, Mcguire JF, et al. Rapid onset functional tic-like behaviors in young females during the COVID-19 pandemic. Mov Disord. 2021;36(12):2707–2713. doi:10.1002/mds.28778

42. Hirschtritt ME, Lee PC, Pauls DL, et al. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry. 2015;72(4):325–333. doi:10.1001/jamapsychiatry.2014.2650

43. Meier SM, Dalsgaard S, Mortensen PB, et al. Mortality risk in a nationwide cohort of individuals with tic disorders and with tourette syndrome. Mov Disord. 2017;32(4):605–609. doi:10.1002/mds.26939

44. Claudio-Campos K, Stevens D, Koo SW, et al. Is persistent motor or vocal tic disorder a milder form of tourette syndrome? Mov Disord. 2021;36(8):1899–1910. doi:10.1002/mds.28593

45. Müller-Vahl KR, Sambrani T, Jakubovski E. Tic disorders revisited: introduction of the term “tic spectrum disorders. Eur Child Adolesc Psychiatry. 2019;28(8):1129–1135. doi:10.1007/s00787-018-01272-7

46. Martino D, Pringsheim TM, Cavanna AE, et al. Systematic review of severity scales and screening instruments for tics: critique and recommendations. Mov Disord. 2017;32(3):467–473. doi:10.1002/mds.26891

47. Wand R, Shady G, Broder R, et al. Tourette syndrome: issues in diagnosis. Neurosci Biobehav Rev. 1992;16(4):449–451. doi:10.1016/S0149-7634(05)80186-1

48. Mol Debes NM, Hjalgrim H, Skov L. Limited knowledge of Tourette syndrome causes delay in diagnosis. Neuropediatrics. 2008;39(2):101–105. doi:10.1055/s-2008-1081457

49. Hartmann A, Millet B. Repetitive movements and behaviors in neurological and psychiatric practice: distinctions and similarities between Tourette disorder and obsessive-compulsive disorder. Rev Neurol. 2018;174(4):199–202. doi:10.1016/j.neurol.2018.01.364

50. Szejko N, Müller-Vahl KR. Challenges in the diagnosis and assessment in patients with tourette syndrome and comorbid obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2021;17:1253–1266. doi:10.2147/NDT.S251499

51. Ganos C, Martino D, Espay AJ, et al. Tics and functional tic-like movements: can we tell them apart? Neurology. 2019;93(17):750–758. doi:10.1212/WNL.0000000000008372

52. Deng H, K Gao, Jankovic J. The genetics of Tourette syndrome. Nat Rev Neurol. 2012;8(4):203–213. doi:10.1038/nrneurol.2012.26

53. Fernandez TV. Genetics of Tourette Syndrome. Psychiatr Clin North Am. 2025;48(1):1–13. doi:10.1016/j.psc.2024.08.002

54. Dietrich A, Fernandez TV, King RA, et al. The Tourette international collaborative genetics (TIC Genetics) study, finding the genes causing Tourette syndrome: objectives and methods. Eur Child Adolesc Psychiatry. 2015;24(2):141–151. doi:10.1007/s00787-014-0543-x

55. Qi Y, Zheng Y, Li Z, et al. Progress in genetic studies of Tourette’s Syndrome. Brain Sci. 2017;7(10):134. doi:10.3390/brainsci7100134

56. Clarke RA, Lee S, Eapen V. Pathogenetic model for Tourette syndrome delineates overlap with related neurodevelopmental disorders including Autism. Transl Psychiatry. 2012;2(9):e158. doi:10.1038/tp.2012.75

57. Eysturoy AN, Skov L, Debes NM. Genetic predisposition increases the tic severity, rate of comorbidities, and psychosocial and educational difficulties in children with Tourette syndrome. J Child Neurol. 2015;30(3):320–325. doi:10.1177/0883073814538668

58. Chou IC, Lin HC, Wang CH, et al. Polymorphisms of interleukin 1 gene IL1RN are associated with Tourette syndrome. Pediatr Neurol. 2010;42(5):320–324. doi:10.1016/j.pediatrneurol.2010.01.006

59. Chen K, Budman CL, Diego Herrera L, et al. Prevalence and clinical correlates of explosive outbursts in Tourette syndrome. Psychiatry Res. 2013;205(3):269–275. doi:10.1016/j.psychres.2012.09.029

60. Abdulkadir M, Yu D, Osiecki L, et al. Investigation of gene-environment interactions in relation to tic severity. J Neural Transm. 2021;128(11):1757–1765. doi:10.1007/s00702-021-02396-y

61. Fichna JP, Chiliński M, Halder AK, et al. Structural variants and implicated processes associated with familial Tourette syndrome. Int J Mol Sci. 2024;25(11):5758. doi:10.3390/ijms25115758

62. Yu D, Sul JH, Tsetsos F, et al. Interrogating the genetic determinants of tourette’s syndrome and other tic disorders through genome-wide association studies. Am J Psychiatry. 2019;176(3):217–227. doi:10.1176/appi.ajp.2018.18070857

63. Cao X, Zhang Y, Abdulkadir M, et al. Whole-exome sequencing identifies genes associated with Tourette’s disorder in multiplex families. Mol Psychiatry. 2021;26(11):6937–6951. doi:10.1038/s41380-021-01094-1

64. Marín O. Developmental timing and critical windows for the treatment of psychiatric disorders. Nat Med. 2016;22(11):1229–1238. doi:10.1038/nm.4225

65. Mink JW. Basal ganglia dysfunction in Tourette’s syndrome: a new hypothesis. Pediatr Neurol. 2001;25(3):190–198. doi:10.1016/S0887-8994(01)00262-4

66. Kalanithi PS, Zheng W, Kataoka Y, et al. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proc Natl Acad Sci U S A. 2005;102(37):13307–13312. doi:10.1073/pnas.0502624102

67. Ganos C, Roessner V, Münchau A. The functional anatomy of Gilles de la Tourette syndrome. Neurosci Biobehav Rev. 2013;37(6):1050–1062. doi:10.1016/j.neubiorev.2012.11.004

68. Kataoka Y, Kalanithi PS, Grantz H, et al. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol. 2010;518(3):277–291. doi:10.1002/cne.22206

69. Tremblay L, Worbe Y, Thobois S, et al. Selective dysfunction of basal ganglia subterritories: from movement to behavioral disorders. Mov Disord. 2015;30(9):1155–1170. doi:10.1002/mds.26199

70. Rawji V, Modi S, Latorre A, et al. Impaired automatic but intact volitional inhibition in primary tic disorders. Brain. 2020;143(3):906–919. doi:10.1093/brain/awaa024

71. Atkinson-Clement C, Porte CA, de Liege A, et al. Impulsive prepotent actions and tics in Tourette disorder underpinned by a common neural network. Mol Psychiatry. 2021;26(7):3548–3557. doi:10.1038/s41380-020-00890-5

72. Jackson GM, Draper A, Dyke K, et al. Inhibition, disinhibition, and the control of action in tourette syndrome. Trends Cognit Sci. 2015;19(11):655–665.

73. Maia TV, Conceição VA. Dopaminergic disturbances in tourette syndrome: an integrative account. Biol Psychiatry. 2018;84(5):332–344. doi:10.1016/j.biopsych.2018.02.1172

74. Palminteri S, Pessiglione M. Reinforcement learning and Tourette syndrome. Int Rev Neurobiol. 2013;112:131–153.

75. Delorme C, Salvador A, Valabrègue R, et al. Enhanced habit formation in Gilles de la Tourette syndrome. Brain. 2016;139(Pt 2):605–615. doi:10.1093/brain/awv307

76. Conceição VA, Dias Â, Farinha AC, et al. Premonitory urges and tics in Tourette syndrome: computational mechanisms and neural correlates. Curr Opin Neurobiol. 2017;46:187–199. doi:10.1016/j.conb.2017.08.009

77. Jackson SR, Loayza J, Crighton M, et al. The role of the insula in the generation of motor tics and the experience of the premonitory urge-to-tic in Tourette syndrome. Cortex. 2020;126:119–133. doi:10.1016/j.cortex.2019.12.021

78. Dong CD, Shi HS, Chu Q, et al. Utilizing network pharmacology to explore the underlying mechanism of Qiangzhi decoction in treating Tourette’s syndrome. Ann Palliat Med. 2020;9(6):4194–4210. doi:10.21037/apm-20-2158

79. Adamczyk A, Gause CD, Sattler R, et al. Genetic and functional studies of a missense variant in a glutamate transporter, SLC1A3, in Tourette syndrome. Psychiatr Genet. 2011;21(2):90–97. doi:10.1097/YPG.0b013e328341a307

80. Lu MQ, Shi ZG, Shang J, et al. Network pharmacology combined with animal models to investigate the mechanism of changpu yujin tang in the treatment of Tourette syndrome. Comb Chem High Throughput Screen. 2024;28:166–84.

81. Qu S, Qiao M, Wang J, et al. Network pharmacology and data mining approach reveal the medication rule of traditional Chinese medicine in the treatment of premenstrual syndrome/premenstrual dysphoric disorder. Front Pharmacol. 2022;13:811030. doi:10.3389/fphar.2022.811030

82. Fan Liu, Lijie W, Tonghao Z. Effect of Jianpi Shugan Huatan Decoction on neurotransmitter secretion in children with Tourette syndrome. Clin Med Pract. 2024;33(05):354–357.

83. Shan LIU, Yan TANG, Youhong LIU. Clinical study of Changma Xifeng Tablets combined with haloperidol in the treatment of children with Tourette syndrome. Modern Med Clin. 2022;37(10):2311–2315.

84. Xiaofen Q. Effect of Xifeng granule combined with psychological intervention therapy on children with tourette syndrome. Chinese J Med Clin Pract. 2019;19(23):4031–4033.

85. Yao Z, Miao T, Lei Y, et al. Effect of acupuncture combined with Anshen Zhichou Granule on neurotransmitters and nerve function in children with multiple tic disorders of heart-liver fire type. Shanghai J Acupuncture Moxibustion. 2023;42(06):604–609.

86. Beiru P, Lixin Y, Weijia Z. Effect observation of auricular point combined with Yizhiningshenye on Tourette syndrome. New Trad ChiN Med. 2016;48(07):183–185.

87. Qi H, Liu R, Zheng W, et al. Efficacy and safety of traditional Chinese medicine for Tourette’s syndrome: a meta-analysis of randomized controlled trials. Asian J Psychiatr. 2020;47:101853. doi:10.1016/j.ajp.2019.101853

88. Wang X, Zhang A, Sun H, et al. Traditional Chinese medicine: current state, challenges, and applications. Serum Pharmacochem Tradit Chin Med. 2017;1:1–6.

89. Zhai Y, Liu L, Zhang F, et al. Network pharmacology: a crucial approach in traditional Chinese medicine research. Chin Med. 2025;20(1):8. doi:10.1186/s13020-024-01056-z

90. Adams D, Wu T, Yasui Y, et al. Systematic reviews of TCM trials: how does inclusion of Chinese trials affect outcome? J Evid Based Med. 2012;5(2):89–97. doi:10.1111/j.1756-5391.2012.01173.x

91. chung VC, Ho RS, Wu X, et al. Incorporating traditional Chinese medicine syndrome differentiation in randomized trials: methodological issues. Eur J Integr Med. 2016;8(6):898–904. doi:10.1016/j.eujim.2016.08.164

Autism-related behaviors and susceptibility to seizures both arise from hyperactivity in a key region of a sensory-information-processing circuit in the brain, a new study finds. The results may help explain the frequent co-occurrence of autism and epilepsy and point to a new therapeutic target.

According to current estimates, about 12 percent of people with autism experience seizures, exceeding the less than 1 percent of people with epilepsy in the general population. Researchers have long attributed the overlap between autism and epilepsy to an imbalance of excitation and inhibition in the brain, says Joseph Gleeson, professor of neuroscience at the University of California, San Diego, who did not contribute to the new work.

But this study really “drills down” into a specific brain circuit and cell type that may be involved in both autism and epilepsy, Gleeson adds. “There’s an incredible level of mechanistic insight in the paper.”

The work focuses on the thalamocortical circuit, which is involved in sensory processing, cognition and other important functions. Dysfunction in this pathway may be implicated in both autism and epilepsy, prior studies suggest.

The investigators on the new study examined the CNTNAP2–knockout mouse model of autism, which, in addition to exhibiting autism-related behaviors—such as hyperactivity, disrupted sleep and impaired sensory processing—is also prone to seizures. They zoomed in on electrical activity within a small region called the reticular thalamic nucleus. This thin, shell-like structure sends inhibitory signals to the thalamus, which ultimately makes the reticular thalamic nucleus a gatekeeper for processes that depend on the thalamocortical circuit.

The findings were published 20 August in Science Advances.

R

eticular thalamic nucleus cells of CNTNAP2 mice show heightened excitability—with an increase in high-frequency action potentials compared with wildtype animals, the investigators found. This was linked to an increase in neural rhythms within the thalamocortical circuit, which arises because of a unique feature of certain thalamic cells, called “post-inhibitory rebound firing,” in which inhibition can paradoxically lead to an increase in activity. These effects were driven by an increase in the function of a specific type of ion channel called T-type calcium channels, the team further observed.

Injecting the CNTNAP2 mice with Z944, a drug that selectively blocks T-type calcium channels and has previously shown anti-epilepsy effects in animals, suppressed seizures and reversed autism-like behaviors, such as repetitive movements and impairments in social behavior.

Inhibiting activity in the reticular thalamic nucleus using chemogenetics produced similar effects. On the other hand, using chemogenetics to enhance activity in this brain structure introduced autism-like behaviors in wildtype mice.

These results suggest that, at least in a subset of autistic people who carry variants in the CNTNAP2 gene, certain drugs used to treat epilepsy may ease autism-related behaviors, says study investigator John Huguenard, professor of neurology and neurological sciences at Stanford University.

The mice in the study do not perfectly model autism, though, and work with other autism models is needed before drawing firm conclusions, Huguenard adds. “I think this is super exciting, but it’s the kind of thing you want to see some replication [of] in other studies before you push ahead for clinical application.”

The findings jibe with independent evidence that the same thalamocortical circuit malfunctions in other autism models, although in different ways, says Zhanyan Fu, associate director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, who was not involved in the new research. For example, reticular thalamic nucleus neurons are hypoactive, rather than hyperactive, in autism model mice missing part of the PTCHD1 gene, a 2016 study found. “I was very excited to see this [new study],” Fu says.

Putting the studies together, the work points to the importance of balance in the activity of the reticular thalamic nucleus, which serves as a “gateway of information flow” within the thalamocortical circuit, according to Fu. But the fact that the new findings suggest different pathophysiological mechanisms underlying autism-related behaviors than past work within the same pathway reinforces the notion that autism is not a single entity and instead involves multiple subgroups, Fu says.

Published on
11/09/2025 – 6:00 GMT+2

Deaths from chronic diseases such as cancer, heart disease, and neurological conditions have fallen in most of the world – but progress has stalled in recent years, according to a new global analysis.

Researchers from the World Health Organization (WHO), Imperial College London, and elsewhere estimated the risk of dying from chronic diseases in 185 countries and territories.

They found that chronic disease mortality fell in about 80 per cent of countries worldwide in the 2010s – but that these improvements were much slower than a decade earlier, particularly in wealthy countries in Europe, North America, Asia, and the Pacific region.

Globally, the burden of chronic diseases “remains unacceptably high,” Leanne Riley, one of the study’s authors and head of the WHO’s surveillance, monitoring, and reporting unit, said in a statement.

Among wealthy developed countries, the worst performers included Germany, which saw some of the smallest declines in chronic disease deaths in the 2010s, scoring better than only the United States. While mortality fell overall in Germany, women in their 30s and those aged 65 to 75 saw small increases tied to lung cancer and dementia deaths.

Meanwhile, three Nordic countries – Denmark, Norway, and Sweden – saw some of the greatest improvements among wealthy Western countries, and there was little slowdown in the 2010s, the report found. That’s due largely to falling deaths among working-age adults.

The researchers dubbed Denmark the West’s “regional benchmark” for chronic disease deaths.

Countries in Central and Eastern Europe generally saw improvements in the 2010s, with Moldova experiencing the greatest decline in chronic disease risk. In Russia and some other countries in the region, alcohol control policies are thought to have played an important role, the researchers said.

The study was published in The Lancet medical journal ahead of a high-level meeting at the United Nations General Assembly later this month that will focus on chronic diseases.

Countries are expected to sign off on a political commitment to curb chronic diseases and boost mental health, though these agreements often do not translate to national policies or increased funding.

The researchers said their findings underscore the need for more investment to address chronic diseases and called for efforts to ensure solutions reach the people who are most affected by these health issues.

Majid Ezzati, one of the study’s authors and a professor at Imperial College London, cited tobacco and alcohol control policies, access to diabetes medication, cancer screenings, and heart attack treatments as key priorities.

“In many countries, effective healthcare programmes … may not be reaching the people who need them, and they are being left out of the health system,” Ezzati said.

SYDNEY, Sept. 11, 2025 /PRNewswire/ — HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the “Most Promising CAR-T Pipeline in APAC” at the Asia Pacific CGT Excellence Awards 2025, held in Singapore last night.

The award recognises companies demonstrating outstanding innovation, scientific excellence, and translational potential in the rapidly evolving CAR T therapy sector. This accolade highlights HaemaLogiX’s role as a leader in advancing CAR T-cell therapies that have the potential to transform outcomes for patients with multiple myeloma across Asia Pacific and beyond.

“This award is wonderful recognition of not just our science, but also the dedication and vision that drives our work,” said Rosanne Dunn, Founder and Chief Scientific Officer of HaemaLogiX. “We’re honoured to be recognised in such exceptional company – a field of the region’s top innovators – all striving to redefine what’s possible in CAR T-cell therapy. We’re more determined than ever to advance transformative therapies, particularly for multiple myeloma – the world’s second largest blood cancer and a disease for which there is currently no cure.”

HaemaLogiX’s immunotherapies bind to unexploited and unique targets (antigens) on the surface of cancerous plasma cells. These antigens are called kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA), and importantly they are not present on normal plasma cells. This provides on-target efficacy and reduced off-tumour toxicity thus preserving immune function and offering a key differentiation to current treatment options. Approximately 70% of multiple myeloma patients are kappa-type and would express KMA and 30% are lambda-type and would express LMA on their myeloma plasma cells. Multiple myeloma patients only express one or the other antigen on their myeloma plasma cells.

About Multiple Myeloma

Multiple myeloma is a malignant disorder of plasma cells within the bone marrow. The world’s second most common blood cancer, approximately 188,000 new cases are diagnosed globally each year. Approximately 60% of patients fail standard-of-care and progress to subsequent lines of therapy with poorer outcomes, with ~42% of patients not living more than five years past diagnosis. This underscores the great unmet medical need for safer and more efficacious treatment options.

ENDS

References:

1.  CGT = Cell and Gene Therapy